| 56.47 Data as of May 21 |  +0.73 / +1.31%Today’s Change | 24.12 Today|||52-Week Range 57.10 | +53.76% Year-to-Date |
| M2M case study: Drug effectiveness receives boost May 21 / FT.com | Pipeline Progress at Gilead - Analyst Blog May 16 / Zacks.com |
| Gilead Sciences Inc (GILD): Today's Featured Drugs Winner May 21 / TheStreet.com | ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up May 15 / TheStreet.com |
| Cramer's Top Stock Picks: SAVE GILD BMY HTA TSLA May 21 / TheStreet.com | ASCO '13 Preview: Gilead's Big Cancer Debut May 15 / TheStreet.com |
| 5 Stocks Underperforming Today In The Drugs Industry May 20 / TheStreet.com | 5 Stocks Boosting The Drugs Industry Higher May 15 / TheStreet.com |
| 'Mad Money' Lightning Round: Magnum Hunter Blew It May 17 / TheStreet.com | Gilead Reaches New 52-Week High (GILD) May 15 / TheStreet.com |
| Previous close | 55.74 |
| Today’s open | 56.14 |
| Day’s range | -- - -- |
| Volume | 10,089,914 |
| Average volume (3 months) | 11,757,411 |
| Market cap | $86.1B |
| Dividend yield | -- |
| Earnings growth (last year) | -7.61% |
| Earnings growth (this year) | +0.48% |
| Earnings growth (next 5 years) | +25.50% |
| Revenue growth (last year) | +13.58% |
| P/E ratio | 31.5 |
| Price/Sales | 5.79 |
| Price/Book | 9.21 |
| Today’s change | Today’s % change | |
|---|---|---|
| AMGNAmgen Inc | +2.06 | +2.02% |
| BIIBBiogen Idec Inc | +6.15 | +2.73% |
| BAXBaxter International... | +0.10 | +0.14% |
| LIFELife Technologies Co... | +0.11 | +0.15% |
| Next reporting date | July 23, 2013 |
| EPS forecast (this quarter) | $0.50 |
| Annual revenue (last year) | $9.6B |
| Annual profit (last year) | $2.6B |
| Net profit margin | 26.96% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer John C. Martin, PhD, MBA |
President & Chief Operating Officer John F. Milligan, PhD |
Corporate headquarters Foster City, California |
.
